Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
Want to see DE:LS60 full AI Analyst Report?
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.19 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€12.34M
Enterprise Value€99.49M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€3.49M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From ConsumablesCLS's device-plus-consumables model creates a durable attached revenue stream: once systems are installed, hospitals buy single-use fibers and accessories repeatedly. This recurring demand can stabilize revenue per installed unit, improve lifetime customer value, and support margin recovery as installed base grows.
Low Financial LeverageEffectively zero reported debt gives CLS financial flexibility while it scales commercial adoption. Low leverage reduces short-term default risk, makes future fundraising less constrained, and preserves optionality to invest in clinical trials, commercialization, or product development without immediate solvent strain.
Niche In Minimally Invasive, Image-guided OncologyCLS targets a structural trend toward minimally invasive, image-guided cancer treatments. Specialization in laserthermia tied to MRI/ultrasound guidance can differentiate the company clinically and align with hospital demand for procedures that reduce patient recovery times, supporting durable market positioning if clinical adoption expands.
Bears Say
Persistent Heavy Losses And Negative MarginsDeep operating losses and a negative gross margin imply the business currently cannot cover product or direct costs at scale. Without a credible path to positive unit economics, continued losses will erode equity, constrain reinvestment, and make long-term competitiveness and independent sustainability highly dependent on external capital or rapid margin improvement.
Weak Cash Generation And Ongoing Cash BurnMaterial negative operating and free cash flows necessitate continued financing to fund operations and commercialization. Even with some burn reduction, persistent outflows limit the company's ability to scale sales, support clinical evidence generation, and invest in product improvements without dilution or additional debt, raising execution risk.
Small, Volatile And Declining Revenue BaseA small, inconsistent revenue base reduces fixed-cost absorption and weakens the installed-base economics that underlie recurring consumable sales. Declining revenue trends hinder momentum for adoption, make forecasting and investment planning difficult, and increase the time and capital required to reach self-sustaining profitability.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.19 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €12.34M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is Aug 14, 2026 which is in 82 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on May 12, 2026. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 64.835%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―